Swayze Eric

SEC source: 0000874015-26-000211 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 21,759

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.46 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-26-000125 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,361

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 27, 2026. These shares may not be sold until August 27, 2026.

SEC source: 0000874015-26-000111 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,105

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.765 to $82.315 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-26-000111 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,312

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.76 to $81.76 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-26-000102 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,747

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.925 to $82.94 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-26-000102 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,926

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the performance period of the grant to the reporting person reported on January 18, 2023. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 167.27% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 200% based on actual achievement of the goal.

SEC source: 0000874015-26-000072 · edgardoc.xml · nonDerivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 318

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-26-000072 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,935

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.26 to $75.48 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-26-000072 · edgardoc.xml · derivative · entry 9

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 611

Underlying: Common Stock · 225 shares

Expires not disclosed

F9 · security: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-26-000072 · edgardoc.xml · derivative · entry 8

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 386

Underlying: Common Stock · 111 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-26-000072 · edgardoc.xml · derivative · entry 7

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,926

Underlying: Common Stock · 9,675 shares

Expires not disclosed

F8 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-26-000072 · edgardoc.xml · derivative · entry 6

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,251

Underlying: Common Stock · 21,366 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F7 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F7 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-26-000072 · edgardoc.xml · derivative · entry 5

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,282

Underlying: Common Stock · 25,800 shares

Expires not disclosed

F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-26-000072 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 367

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-26-000072 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,819

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-26-000026 · edgardoc.xml · derivative · entry 9

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Indirect · by Son

Disclosed balance after: 150

Underlying: Common Stock · 150 shares

Expires 2036-01-01

F5 · derivative.exercise_date: Grant on 01/02/2026 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-26-000026 · edgardoc.xml · derivative · entry 8

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,350

Underlying: Common Stock · 19,350 shares

Expires 2036-01-01

F4 · derivative.exercise_date: Grant on 01/02/2026 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2026. 25% of the shares subject to the option will vest and become exercisable on 01/02/2027. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-26-000026 · edgardoc.xml · derivative · entry 7

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,065

Underlying: Common Stock · 18,338 shares

Expires 2027-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-26-000026 · edgardoc.xml · derivative · entry 6

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,403

Underlying: Common Stock · 5,125 shares

Expires 2027-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-26-000026 · edgardoc.xml · nonDerivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,453

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.88 to $79.70 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-26-000026 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,791

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-26-000026 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,453

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.155 to $78.88 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-26-000026 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000262 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 256

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-25-000262 · edgardoc.xml · derivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 497

Underlying: Common Stock · 125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000262 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 309

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000254 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,453

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.02 to $69.03 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000245 · edgardoc.xml · derivative · entry 7

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,972 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000245 · edgardoc.xml · nonDerivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,302

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.04 to $66.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000245 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,274

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000245 · edgardoc.xml · derivative · entry 6

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,972

Underlying: Common Stock · 14,142 shares

Expires 2026-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000245 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,302

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.04 to $66.23 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000245 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,444

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000224 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,302

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.64 to $53.72 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000224 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,432

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.14 to $49.54 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000103 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,432

F1 · shares: Reporting shares purchased under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on February 28,2025. These shares may not be sold until August 28, 2025.

SEC source: 0000874015-25-000081 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,017

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.99 to $32.86 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000081 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,384

F1 · shares: Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal.

SEC source: 0000874015-25-000065 · edgardoc.xml · nonDerivative · entry 4

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 184

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

SEC source: 0000874015-25-000065 · edgardoc.xml · nonDerivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,670

F2 · kind: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F2 · shares: The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.835 to $32.85 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000065 · edgardoc.xml · derivative · entry 9

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 622

Underlying: Common Stock · 49 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000065 · edgardoc.xml · derivative · entry 8

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 671

Underlying: Common Stock · 245 shares

Expires not disclosed

F9 · security: Grant to reporting person's son of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000065 · edgardoc.xml · derivative · entry 7

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,617

Underlying: Common Stock · 19,111 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000065 · edgardoc.xml · derivative · entry 6

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,728

Underlying: Common Stock · 33,000 shares

Expires not disclosed

F6 · security: Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F7 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F8 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F8 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000065 · edgardoc.xml · derivative · entry 5

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,482

Underlying: Common Stock · 22,000 shares

Expires not disclosed

F4 · security: Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.

F5 · derivative.exercise_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

F5 · derivative.expiration_date: The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated.

SEC source: 0000874015-25-000065 · edgardoc.xml · nonDerivative · entry 3

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-25-000065 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,824

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-25-000031 · edgardoc.xml · derivative · entry 2

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Indirect · by Son

Disclosed balance after: 163

Underlying: Common Stock · 163 shares

Expires 2035-01-01

F2 · derivative.exercise_date: Grant on 01/02/2025 to reporting person's son of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-25-000031 · edgardoc.xml · derivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-01-01

F1 · derivative.exercise_date: Grant on 01/02/2025 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. Following this transaction, the option was exercisable as to 0 shares on 01/02/2025. 25% of the shares subject to the option will vest and become exercisable on 01/02/2026. Thereafter, the remaining shares subject to the option will vest and become exercisable in 36 equal monthly installments over the next 3 years.

SEC source: 0000874015-24-000241 · edgardoc.xml · nonDerivative · entry 1

Swayze Eric · CIK 0001791058 · EVP Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,713

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on August 14, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.90 to $37.95 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.